

Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)

Date: 05/07/2024

Location: Virtual

Minutes: Final

Committee members present:

Adam Firth	Chair	Present for notes 1 - 6
Ramsey Cutress	Topic Adviser	Present for notes 1 - 6
Mark Davies	Medical oncologist	Present for notes 1 - 6
Kay Davies-Crowley	Nurse specialist	Present for notes 1 - 6
Milly Finch	Pharmacist	Present for notes 1 - 6
Rachael Griffin	Lay member	Present until partway through item 5
Sadaf Haque	GP	Present for notes 1 - 6
Katy Tan	Lay member	Present for notes 5 - 6

In attendance:

Sarah Boyce	Senior Technical Analyst	Present for notes 1 - 6
Victoria Carter	Implementation Support Manager	Present for notes 1 - 6
Jen Francis	Guideline Co-ordinator	Present for notes 1 - 4
Gareth Haman	Senior Medical Editor	Present for notes 1 - 6
Marie Harrisingh	Topic Lead	Present for notes 1 - 6
Alfredo Mariani	Senior Health Economist	Present for notes 1 - 6
Yolanda Martinez	Technical Analyst	Present for notes 1 - 6
Adam O'Keefe	Project Manager	Present for notes 1 - 6
Katherine Saxby	Medicines Adviser	Present for notes 1 - 6
Adam Storrow	Business Analyst, Resource Impact Assessment	Present for notes 1 - 6

Apologies:

Kwok Leung Cheung	Breast surgeon
Tim Robinson	Medical oncologist
Elinor Sawyer	Clinical oncologist
David Talbot	Lay member
Ben Thwaites	Pharmacist

Neoadjuvant chemotherapy & OFS update GC1 – minutes.

Lindsay Claxton	Health Economics Adviser, NICE
Andrea Heath	Senior Information Specialist, NICE

1. Welcome, introductions and apologies

The Chair welcomed the committee members and NICE attendees to the first committee meeting for the Neoadjuvant chemotherapy and ovarian function suppression update to the NICE Early and locally advanced breast cancer: diagnosis and management guideline.

The Chair informed the Committee that apologies had been received. These are noted above.

2. Declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Neoadjuvant chemotherapy and ovarian function suppression.

The Chair asked committee members to verbally declare any new interests, no new interests were declared.

3. Meeting Aims

The Chair introduced Marie Harrisingh (MH), Topic Lead, who outlined the objectives of the meeting. MH then provided an explanation of methods used for the evidence review and invited any questions from the committee on the methods training previously provided.

4. Revisit HER2 Review Protocol

MH sought the committee's input on some further queries to have arisen with the Review protocol for the HER2 review.

5. Platinum based neoadjuvant chemotherapy for people with TNBC and gBRCA

The Chair introduced NICE Technical Analyst Yolanda Martinez, Senior Technical Analyst Sarah Boyce and Senior Health Economist Alfredo Mariani who presented the clinical and cost-effectiveness evidence identified for people with TNBC and gBRCA.

The committee discussed the evidence presented and any health inequalities considerations before drafting recommendations

6. AOB, Summary and next steps

Neoadjuvant chemotherapy & OFS update GC1 – minutes.

The Chair outlined next steps following the meeting, thanked the committee for their contributions, summarised the main actions from the day and asked for items of any other business. As there was no further business to discuss, the Chair brought the meeting to a close.

Date of next meeting: 06/09/2024

Location of next meeting: Virtual